$0.84
-0.02 (-2.88%)
Open$0.86
Previous Close$0.86
Day High$0.88
Day Low$0.83
52W High$55.00
52W Low$0.81
Volume—
Avg Volume373.0K
Market Cap8.90M
P/E Ratio—
EPS$-107.92
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,206.6% upside
Current
$0.84
$0.84
Target
$27.66
$27.66
$20.34
$27.66 avg
$35.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.53M | 1.54M | 1.49M |
| Net Income | 146.8K | 155.5K | 142.3K |
| Profit Margin | 9.6% | 10.1% | 9.6% |
| EBITDA | 279.3K | 246.3K | 227.4K |
| Free Cash Flow | 124.0K | 159.2K | 163.1K |
| Rev Growth | +19.5% | +5.1% | +5.0% |
| Debt/Equity | 0.44 | 0.57 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |